$36.58
-2.5%Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Chief Financial Officer, Treasurer & Secretary
Compensation
$547,336
President, Chief Executive Officer & Director
Compensation
$939,031
During the last 12 months, insiders have sold $1.21M worth of ELMD shares, with no buying activity reported.
0
0.00
8.2K
280.06K
-280K
-$280K
0
0.00
0
0.00
+0
+$0
0
0.00
39.4K
932.43K
-932K
-$932K
0
0.00
0
0.00
+0
+$0
No buying activity
Summers Andrew
Director
$932K
Skarvan Kathleen
Director
$280K
Strong bearish signal with $1.21M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
ELMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | September 30, 2025 | November 14, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | October 01, 2024 | November 15, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | September 26, 2023 | November 10, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | September 27, 2022 | November 11, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | September 30, 2021 | November 12, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | September 29, 2020 | November 13, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | September 27, 2019 | November 15, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | September 28, 2018 | November 16, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | September 26, 2017 | November 10, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | October 03, 2016 | November 11, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.